Patent: 9,474,688

Summary for Patent: 9,474,688

Scope and claims summary:

Title:	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
Abstract:	The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient.
Inventor(s):	Weeks; Wendell Porter (Corning, NY), Schaut; Robert Anthony (Painted Post, NY), DeMartino; Steven Edward (Painted Post, NY), Peanasky; John Stephen (Big Flats, NY)
Assignee:	Corning Incorporated (Corning, NY)
Application Number:	13/660,680
Patent Claims:	see list of patent claims

Details for Patent 9,474,688

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	October 28, 1982	9,474,688	2031-10-25
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	December 29, 2015	9,474,688	2031-10-25
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	August 06, 1998	9,474,688	2031-10-25
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	March 31, 1994	9,474,688	2031-10-25
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	May 25, 2018	9,474,688	2031-10-25
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	June 25, 1991	9,474,688	2031-10-25
Novo Nordisk Inc.	NOVOLIN R	insulin human	Injection	019938	June 01, 2018	9,474,688	2031-10-25